Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle SocietyGlobeNewsWire • 10/02/19
Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019GlobeNewsWire • 10/01/19
Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report?Zacks Investment Research • 09/07/19
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019GlobeNewsWire • 09/04/19
Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses24/7 Wall Street • 08/26/19
Amicus Should Be On Your Radar As It Makes Progress On Multiple Fronts Using Gene TherapySeeking Alpha • 08/15/19
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?Zacks Investment Research • 06/07/19
Amicus Therapeutics: Galvanizing Growth By Capturing The Tides Of Gene TherapySeeking Alpha • 05/09/19
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19
Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/30/19